Access the full text.
Sign up today, get DeepDyve free for 14 days.
Loading next page...
/lp/oxford-university-press/a-full-pull-program-for-the-provision-of-pharmaceuticals-practical-wwrnuYONLj
References (17)
-
M. Selgelid, Eline Sepers (2006)
Patents, profits, and the price of pills: implications for access and availability -
Joseph Lyon (1999)
Nuclear weapons testing and research efforts to evaluate health effects on exposed populations in the United States.Epidemiology, 10 5
-
J. Murray, A. López (1996)
The Global Burden of Disease -
Christopher Murray, Alan Lopez (2000)
Progress and directions in refining the global burden of disease approach: a response to Williams.Health economics, 9 1
-
Christopher Murray, A. Acharya (1997)
Understanding DALYs (disability-adjusted life years).Journal of health economics, 16 6
-
A. Williams (2000)
Comments on the response by Murray and Lopez.Health economics, 9 1
-
Alan Lopez, C. Mathers, M. Ezzati, D. Jamison, Murray Cjl (2006)
Sensitivity and Uncertainty Analyses for Burden of Disease and Risk Factor Estimates -- Global Burden of Disease and Risk Factors -
C. Mathers, Joshua Salomon, M. Ezzati, Stephen Begg, S. Hoorn, Alan Lopez (2006)
Sensitivity and Uncertainty Analyses for Burden of Disease and Risk Factor Estimates -
J. Kaplan, J. Kaplan (2000)
The Limits and Lies of Human Genetic Research -
Mason Jb, P. Musgrove, Habicht Jp (2003)
At least one-third of poor countries disease burden is due to malnutrition. -
A. Attaran (2004)
How do patents and economic policies affect access to essential medicines in developing countries?Health affairs, 23 3
-
.. Murray (1997)
Global burden of diseaseThe Lancet, 350
-
D. Brock (2004)
Ethical Issues in the Use of Cost Effectiveness Analysis for the Prioritization of Health Resources -
Christopher Murray, A. Lopez (1999)
On the comparable quantification of health risks: lessons from the Global Burden of Disease Study.Epidemiology, 10 5
-
Thomas Pogge (2005)
World Poverty and Human RightsEthics & International Affairs, 19
-
S. Anand, K. Hanson (1997)
Disability-adjusted life years: a critical review.Journal of health economics, 16 6
-
Alan Williams (1999)
Calculating the global burden of disease: time for a strategic reappraisal?Health economics, 8 1
- Publisher
- Oxford University Press
- Copyright
- The Author 2008. Published by Oxford University Press. Available online at www.phe.oxfordjournals.org
- Subject
- Original Article
- ISSN
- 1754-9973
- eISSN
- 1754-9981
- DOI
- 10.1093/phe/phn022
- Publisher site
- See Article on Publisher Site
Abstract
Thomas Pogge has proposed a supplement to the standard patent regime whereby innovating companies would be rewarded in proportion to the extent to which their innovations lead to reduction of the global burden of disease (GBD). This paper argues that an expansion of this proposalwhereby provision of already existing medicines are incentivised in a similar waywould provide a more comprehensive solution to the healthcare situation in developing countries. It then considers the practical challenges that the implementation of such a proposal (expanded or otherwise) would entail. Though these include difficulties associated with disease burden metric, I argue that the most serious difficulties are associated with the problem of causal attribution. A basic idea underlying Pogge's proposal is that the disease burden reduction attributable to particular interventions can be determined. Theoretically speaking, in cases involving multiple interacting causal factors, there may be no fact of the matter regarding the extent to which disease burden reduction should be attributed to one intervention as opposed to another; and (even if workable practical solutions to this theoretical challenge can be met) the data requirements for implementation would be daunting.
Journal
Public Health Ethics – Oxford University Press
Published: Jul 27, 2008